EGFR and non-small cell lung carcinoma: Among a multitude of targeted agents explored for the treatment of advanced NSCLC, small molecule tyrosine kinase inhibitors (TKI), gefitinib and erlotinib, targeting a mutant epidermal growth factor receptor (EGFR) have shown significant benefit in clinics.